Brokerages expect Align Technology, Inc. (NASDAQ:ALGN) to announce sales of $395.55 million for the current quarter, according to Zacks Investment Research. Six analysts have provided estimates for Align Technology’s earnings, with the highest sales estimate coming in at $397.40 million and the lowest estimate coming in at $392.50 million. Align Technology posted sales of $293.20 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 34.9%. The company is scheduled to report its next earnings results on Tuesday, January 30th.
According to Zacks, analysts expect that Align Technology will report full year sales of $395.55 million for the current fiscal year, with estimates ranging from $1.44 billion to $1.45 billion. For the next financial year, analysts forecast that the business will post sales of $1.79 billion per share, with estimates ranging from $1.70 billion to $1.89 billion. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Align Technology.
Align Technology (NASDAQ:ALGN) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $1.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.82 by $0.19. The firm had revenue of $385.30 million for the quarter, compared to analyst estimates of $359.80 million. Align Technology had a return on equity of 25.60% and a net margin of 19.98%. The company’s revenue for the quarter was up 38.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.63 earnings per share.
Shares of Align Technology (NASDAQ:ALGN) opened at $260.88 on Friday. The stock has a market capitalization of $20,920.00, a PE ratio of 78.18, a P/E/G ratio of 2.52 and a beta of 1.41. Align Technology has a 12-month low of $88.56 and a 12-month high of $266.41.
In other Align Technology news, VP Emory Wright sold 5,025 shares of the company’s stock in a transaction dated Tuesday, November 28th. The shares were sold at an average price of $263.68, for a total value of $1,324,992.00. Following the sale, the vice president now owns 80,762 shares in the company, valued at $21,295,324.16. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Greg J. Santora sold 7,700 shares of the stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $238.95, for a total transaction of $1,839,915.00. The disclosure for this sale can be found here. Insiders sold a total of 23,125 shares of company stock valued at $5,739,059 over the last quarter. 1.60% of the stock is owned by corporate insiders.
A number of institutional investors have recently modified their holdings of the stock. Crossmark Global Holdings Inc. purchased a new position in Align Technology in the third quarter valued at approximately $2,875,000. Rhumbline Advisers lifted its holdings in Align Technology by 4.9% in the third quarter. Rhumbline Advisers now owns 150,816 shares of the medical equipment provider’s stock valued at $28,092,000 after acquiring an additional 7,032 shares during the period. Oppenheimer & Co. Inc. acquired a new position in shares of Align Technology during the 2nd quarter worth $1,768,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Align Technology during the 2nd quarter worth $454,000. Finally, Aperio Group LLC raised its stake in Align Technology by 38.5% in the 3rd quarter. Aperio Group LLC now owns 42,818 shares of the medical equipment provider’s stock valued at $7,976,000 after purchasing an additional 11,892 shares during the last quarter. Institutional investors own 83.88% of the company’s stock.
WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/01/analysts-expect-align-technology-inc-algn-will-post-quarterly-sales-of-395-55-million.html.
About Align Technology
Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.